Michael P Brown

Michael P Brown

UNVERIFIED PROFILE

Are you Michael P Brown?   Register this Author

Register author
Michael P Brown

Michael P Brown

Publications by authors named "Michael P Brown"

Are you Michael P Brown?   Register this Author

98Publications

4733Reads

42Profile Views

Thymic hyperplasia following double immune checkpoint inhibitor therapy in two patients with stage IV melanoma.

Asia Pac J Clin Oncol 2019 Aug 1. Epub 2019 Aug 1.

Department of Medicine, Royal Darwin Hospital, Darwin, Northern Territory, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ajco.13233DOI Listing
August 2019

Optimization of manufacturing conditions for chimeric antigen receptor T cells to favor cells with a central memory phenotype.

Cytotherapy 2019 Jun 8;21(6):593-602. Epub 2019 Apr 8.

Translational Oncology Laboratory, Centre for Cancer Biology, University of South Australia and SA Pathology, Adelaide, South Australia, Australia; Cancer Clinical Trials Unit, Royal Adelaide Hospital, Adelaide, South Australia, Australia; School of Medicine, the University of Adelaide, Adelaide, South Australia, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jcyt.2019.03.003DOI Listing
June 2019

Cancer outcomes in patients requiring immunosuppression in addition to corticosteroids for immune-related adverse events after immune checkpoint inhibitor therapy.

Asia Pac J Clin Oncol 2019 Jun 19. Epub 2019 Jun 19.

Cancer Clinical Trials Unit, Royal Adelaide Hospital, Adelaide, South Australia, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ajco.13177DOI Listing
June 2019

Clinical chimeric antigen receptor-T cell therapy: a new and promising treatment modality for glioblastoma.

Clin Transl Immunology 2019 20;8(5):e1050. Epub 2019 May 20.

Translational Oncology Laboratory Centre for Cancer Biology University of South Australia and SA Pathology Adelaide SA Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cti2.1050DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6526894PMC
May 2019

Glioblastoma heterogeneity and the tumour microenvironment: implications for preclinical research and development of new treatments.

Biochem Soc Trans 2019 04 22;47(2):625-638. Epub 2019 Mar 22.

Centre for Cancer Biology, SA Pathology and University of South Australia, Adelaide, Australia

View Article

Download full-text PDF

Source
http://www.biochemsoctrans.org/lookup/doi/10.1042/BST2018044
Publisher Site
http://dx.doi.org/10.1042/BST20180444DOI Listing
April 2019

APOMAB Antibody-Drug Conjugates Targeting Dead Tumor Cells are Effective .

Mol Cancer Ther 2019 02 9;18(2):335-345. Epub 2018 Nov 9.

Translational Oncology Laboratory, Centre for Cancer Biology, SA Pathology and University of South Australia, Adelaide, SA, Australia.

View Article

Download full-text PDF

Source
http://mct.aacrjournals.org/lookup/doi/10.1158/1535-7163.MCT
Publisher Site
http://dx.doi.org/10.1158/1535-7163.MCT-18-0842DOI Listing
February 2019

Phase I trial of Lipovaxin-MM, a novel dendritic cell-targeted liposomal vaccine for malignant melanoma.

Cancer Immunol Immunother 2018 Sep 16;67(9):1461-1472. Epub 2018 Jul 16.

Center for Cancer Biology, University of South Australia and SA Pathology, Adelaide, SA, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00262-018-2207-zDOI Listing
September 2018

Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study.

Lancet Oncol 2018 05 27;19(5):672-681. Epub 2018 Mar 27.

Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, VIC, Australia; Medical, Dental and Health Sciences, University of Melbourne, Parkville, VIC, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(18)30139-6DOI Listing
May 2018

Logic-gated approaches to extend the utility of chimeric antigen receptor T-cell technology.

Biochem Soc Trans 2018 04 14;46(2):391-401. Epub 2018 Mar 14.

Translational Oncology Laboratory, Centre for Cancer Biology, University of South Australia and SA Pathology, Frome Road, Adelaide, SA 5000, Australia

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1042/BST20170178DOI Listing
April 2018

Antibody drug conjugates and bystander killing: is antigen-dependent internalisation required?

Br J Cancer 2017 Dec 24;117(12):1736-1742. Epub 2017 Oct 24.

Translational Oncology Laboratory, Centre for Cancer Biology, SA Pathology and University of South Australia, Adelaide, SA 5000, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/bjc.2017.367DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5729478PMC
December 2017

A novel series of N-(pyridin-2-yl)-4-(thiazol-5-yl)pyrimidin-2-amines as highly potent CDK4/6 inhibitors.

Future Med Chem 2017 09 10;9(13):1495-1506. Epub 2017 Aug 10.

Centre for Drug Discovery & Development, Sansom Institute for Health Research, School of Pharmacy & Medical Sciences, University of South Australia, Adelaide, South Australia 5001, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4155/fmc-2017-0076DOI Listing
September 2017

Open-label, multicentre safety study of vemurafenib in 3219 patients with BRAF mutation-positive metastatic melanoma: 2-year follow-up data and long-term responders' analysis.

Eur J Cancer 2017 07 11;79:176-184. Epub 2017 May 11.

Cancer Clinical Trials Unit, Royal Adelaide Hospital, Adelaide, Australia; Centre for Cancer Biology, SA Pathology and University of South Australia, Adelaide, Australia; Discipline of Medicine, University of Adelaide, Adelaide, Australia. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2017.04.007DOI Listing
July 2017

Comment on "KB004, a first in class monoclonal antibody targeting the receptor tyrosine kinase EphA3, in patients with advanced hematologic malignancies: Results from a phase 1 study".

Leuk Res 2017 04 9;55:55-57. Epub 2017 Jan 9.

Department of Haematology, SA Pathology, Adelaide, South Australia, Australia; Cancer Theme, South Australia Health and Medical Research Institute (SAHMRI), Adelaide, South Australia, Australia; The University of Adelaide, School of Medicine, Adelaide, South Australia, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.leukres.2017.01.009DOI Listing
April 2017

Autoimmune limbic encephalitis with anti-contactin-associated protein-like 2 antibody secondary to pembrolizumab therapy.

J Neuroimmunol 2017 04 18;305:16-18. Epub 2017 Jan 18.

Royal Adelaide Hospital, North Terrace, Adelaide, South Australia 5000, Australia. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jneuroim.2016.12.016DOI Listing
April 2017

Control of immune cell entry through the tumour vasculature: a missing link in optimising melanoma immunotherapy?

Clin Transl Immunology 2017 Mar 17;6(3):e134. Epub 2017 Mar 17.

Centre for Cancer Biology, University of South Australia and SA Pathology, Adelaide, SA, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/cti.2017.7DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5382436PMC
March 2017

Risk of cumulative toxicity after complete melanoma response with pembrolizumab.

BMJ Case Rep 2017 Feb 1;2017. Epub 2017 Feb 1.

Department of Medical Oncology, Royal Adelaide Hospital, Adelaide, South Australia, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/bcr-2016-218308DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5294005PMC
February 2017

GM-CSF signalling blockade and chemotherapeutic agents act in concert to inhibit the function of myeloid-derived suppressor cells .

Clin Transl Immunology 2016 Dec 23;5(12):e119. Epub 2016 Dec 23.

Translational Oncology, Centre for Cancer Biology, SA Pathology and the University of South Australia, Adelaide, Australia; Cancer Clinical Trials Unit, Royal Adelaide Hospital, Adelaide, Australia; Discipline of Medicine, University of Adelaide, Adelaide, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/cti.2016.80DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5192067PMC
December 2016

Vedolizumab: a novel treatment for ipilimumab-induced colitis.

BMJ Case Rep 2016 Aug 18;2016. Epub 2016 Aug 18.

Department of Gastroenterology, Royal Adelaide Hospital, Adelaide, South Australia, Australia.

View Article

Download full-text PDF

Source
http://casereports.bmj.com/lookup/doi/10.1136/bcr-2016-21664
Publisher Site
http://dx.doi.org/10.1136/bcr-2016-216641DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5015180PMC
August 2016

GD2-specific CAR T Cells Undergo Potent Activation and Deletion Following Antigen Encounter but can be Protected From Activation-induced Cell Death by PD-1 Blockade.

Mol Ther 2016 Jun 29;24(6):1135-1149. Epub 2016 Mar 29.

Translational Oncology Laboratory Centre for Cancer Biology, SA Pathology, and University of South Australia, Adelaide, South Australia; Discipline of Medicine, University of Adelaide, Adelaide, South Australia; Cancer Clinical Trials Unit, Royal Adelaide Hospital, Adelaide, South Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/mt.2016.63DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4923328PMC
June 2016

Multiplexed highly-accurate DNA sequencing of closely-related HIV-1 variants using continuous long reads from single molecule, real-time sequencing.

Nucleic Acids Res 2015 Nov 22;43(20):e129. Epub 2015 Jun 22.

Emory Vaccine Center, Emory University, Atlanta, GA, 30329, USA Pathology and Laboratory Medicine, Emory University, Atlanta, 30322, GA

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/nar/gkv630DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4787755PMC
November 2015

Phase I study evaluating the safety and efficacy of oral panobinostat in combination with radiotherapy or chemoradiotherapy in patients with inoperable stage III non-small-cell lung cancer.

Anticancer Drugs 2015 Nov;26(10):1069-77

aCancer Clinical Trials Unit bDepartment of Medical Oncology cDepartment of Radiation Oncology dDepartment of Medical Imaging, Royal Adelaide Hospital eCentre for Cancer Biology, SA Pathology and University of South Australia fDiscipline of Medicine, University of Adelaide, Adelaide, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CAD.0000000000000282DOI Listing
November 2015

The potential complementary role of targeted alpha therapy in the management of metastatic melanoma.

Melanoma Manag 2015 Nov 24;2(4):353-366. Epub 2015 Nov 24.

Faculty of Medicine, University of Western Sydney, Liverpool, NSW, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/mmt.15.26DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6094593PMC
November 2015

Different cytokine and stimulation conditions influence the expansion and immune phenotype of third-generation chimeric antigen receptor T cells specific for tumor antigen GD2.

Cytotherapy 2015 Apr 6;17(4):487-95. Epub 2015 Jan 6.

Translational Oncology, Centre for Cancer Biology, SA Pathology, and University of South Australia, Adelaide, Australia; Cancer Clinical Trials Unit, Royal Adelaide Hospital, Adelaide, Australia; Discipline of Medicine, University of Adelaide, Adelaide, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jcyt.2014.12.002DOI Listing
April 2015

Phase II study evaluating efficacy and safety of everolimus with letrozole for management of advanced (unresectable or metastatic) non-small cell lung cancer after failure of platinum-based treatment: a preliminary analysis of toxicity.

Cancer Chemother Pharmacol 2015 Feb 11;75(2):325-31. Epub 2014 Dec 11.

Department of Medical Oncology, Royal Adelaide Hospital, Adelaide, SA, 5000, Australia,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-014-2644-0DOI Listing
February 2015

BRAF and MEK inhibition variably affect GD2-specific chimeric antigen receptor (CAR) T-cell function in vitro.

J Immunother 2015 Jan;38(1):12-23

*Translational Oncology Laboratory, Centre for Cancer Biology, SA Pathology, and University of South Australia §Cancer Clinical Trials Unit, Royal Adelaide Hospital ∥Discipline of Medicine, University of Adelaide, Adelaide, SA, Australia †Center for Cell and Gene Therapy, Baylor College of Medicine, The Methodist Hospital and Texas Children's Hospital ‡Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CJI.0000000000000061DOI Listing
January 2015

Scrutinizing calcium flux oscillations in T lymphocytes to deduce the strength of stimulus.

Sci Rep 2015 Jan 14;5:7760. Epub 2015 Jan 14.

Experimental Therapeutics Laboratory, Hanson Institute, Adelaide, SA 5000, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/srep07760DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4293621PMC
January 2015

Could bystander killing contribute significantly to the antitumor activity of brentuximab vedotin given with standard first-line chemotherapy for Hodgkin lymphoma?

Immunotherapy 2014 ;6(4):371-5

Cancer Clinical Trials Unit, MDP 11, Level 4, East Wing, Royal Adelaide Hospital Cancer Centre, Adelaide, SA, 5000, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/imt.14.13DOI Listing
December 2014

Targeted α-therapy using 227Th-APOMAB and cross-fire antitumour effects: preliminary in-vivo evaluation.

Nucl Med Commun 2014 Dec;35(12):1284-90

aTranslational Oncology Laboratory, Centre for Cancer Biology, SA Pathology bSchool of Medicine cSchool of Chemistry and Physics, University of Adelaide dDepartment of Medical Physics eCancer Clinical Trials Unit, Royal Adelaide Hospital fEnvironment Protection Authority SA, Adelaide, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MNM.0000000000000199DOI Listing
December 2014

The atypical chemokine receptor CCX-CKR regulates metastasis of mammary carcinoma via an effect on EMT.

Immunol Cell Biol 2014 Nov 15;92(10):815-24. Epub 2014 Jul 15.

Chemokine Biology Laboratory, Centre for Molecular Pathology, School of Molecular and Biomedical Science, University of Adelaide, Adelaide, South Australia, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/icb.2014.58DOI Listing
November 2014

BRAF and MEK inhibition variably affect GD2-specific chimeric antigen receptor (CAR) T-cell function in vitro.

J Immunother 2015 Jan;38(1):12-23

*Translational Oncology Laboratory, Centre for Cancer Biology, SA Pathology, and University of South Australia §Cancer Clinical Trials Unit, Royal Adelaide Hospital ∥Discipline of Medicine, University of Adelaide, Adelaide, SA, Australia †Center for Cell and Gene Therapy, Baylor College of Medicine, The Methodist Hospital and Texas Children's Hospital ‡Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CJI.0000000000000061DOI Listing
January 2015

Dose selection, pharmacokinetics, and pharmacodynamics of BRAF inhibitor dabrafenib (GSK2118436).

Clin Cancer Res 2014 Sep 23;20(17):4449-58. Epub 2014 Jun 23.

Melanoma Institute Australia and University of Sydney, New South Wales, Australia. Westmead Institute for Cancer Research, Westmead Millennium Institute, and Department of Medical Oncology, Westmead Hospital, Sydney, New South Wales, Australia.

View Article

Download full-text PDF

Source
http://clincancerres.aacrjournals.org/cgi/doi/10.1158/1078-0
Publisher Site
http://dx.doi.org/10.1158/1078-0432.CCR-14-0887DOI Listing
September 2014

Monte Carlo simulations of dose distributions with necrotic tumor targeted radioimmunotherapy.

Appl Radiat Isot 2014 Aug 12;90:40-5. Epub 2014 Mar 12.

Department of Medical Physics, Royal Adelaide Hospital, Adelaide, SA 5000, Australia; School of Chemistry and Physics, University of Adelaide, Adelaide, SA 5005, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.apradiso.2014.03.006DOI Listing
August 2014

Gemcitabine and CHK1 inhibition potentiate EGFR-directed radioimmunotherapy against pancreatic ductal adenocarcinoma.

Clin Cancer Res 2014 Jun 16;20(12):3187-97. Epub 2014 May 16.

Authors' Affiliations: Signal Transduction Laboratory, QIMR Berghofer Medical Research Institute, Herston; Queensland Centre for Medical Genomics, Institute for Molecular Bioscience, The University of Queensland, St Lucia, Queensland; The Kinghorn Cancer Centre, Cancer Division, Garvan Institute of Medical Research; St Vincent's Clinical School, Faculty of Medicine, University of NSW; Department of Anatomical Pathology, SYDPATH, St Vincent's Hospital, Darlinghurst, New South Wales; Australian Pancreatic Cancer Genome Initiative, for the full list of contributors see http://www.pancreaticcancer.net.au/apgi/collaborators; Cancer Clinical Trials Unit, Royal Adelaide Hospital Cancer Centre, and Centre for Cancer Biology, SA Pathology; School of Medicine, University of Adelaide, Adelaide, Australia; and Wolfson Wohl Cancer Research Centre, Institute of Cancer Sciences, University of Glasgow, Glasgow, Scotland, United KingdomAuthors' Affiliations: Signal Transduction Laboratory, QIMR Berghofer Medical Research Institute, Herston; Queensland Centre for Medical Genomics, Institute for Molecular Bioscience, The University of Queensland, St Lucia, Queensland; The Kinghorn Cancer Centre, Cancer Division, Garvan Institute of Medical Research; St Vincent's Clinical School, Faculty of Medicine, University of NSW; Department of Anatomical Pathology, SYDPATH, St Vincent's Hospital, Darlinghurst, New South Wales; Australian Pancreatic Cancer Genome Initiative, for the full list of contributors see http://www.pancreaticcancer.net.au/apgi/collaborators; Cancer Clinical Trials Unit, Royal Adelaide Hospital Cancer Centre, and Centre for Cancer Biology, SA Pathology; School of Medicine, University of Adelaide, Adelaide, Australia; and Wolfson Wohl Cancer Research Centre, Institute of Cancer Sciences, University of Glasgow, Glasgow, Scotland, United Kingdom.

View Article

Download full-text PDF

Source
http://clincancerres.aacrjournals.org/content/early/2014/05/
Web Search
http://clincancerres.aacrjournals.org/content/early/2014/05/
Web Search
http://clincancerres.aacrjournals.org/cgi/doi/10.1158/1078-0
Publisher Site
http://dx.doi.org/10.1158/1078-0432.CCR-14-0048DOI Listing
June 2014

Postchemotherapy and tumor-selective targeting with the La-specific DAB4 monoclonal antibody relates to apoptotic cell clearance.

J Nucl Med 2014 May 27;55(5):772-9. Epub 2014 Mar 27.

Signal Transduction Laboratory, QIMR Berghofer Medical Research Institute, Brisbane, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2967/jnumed.113.130559DOI Listing
May 2014

The use of vemurafenib in Australian patients with unresectable or metastatic melanoma containing the V600 BRAF gene mutation.

Asia Pac J Clin Oncol 2014 Apr;10 Suppl S3:1-15

Cancer Clinical Trials Unit, Royal Adelaide Hospital, Adelaide, South Australia, Australia.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/ajco.12200
Publisher Site
http://dx.doi.org/10.1111/ajco.12200DOI Listing
April 2014

Can cancer registries show whether treatment is contributing to survival increases for melanoma of the skin at a population level?

J Eval Clin Pract 2014 Feb 23;20(1):74-80. Epub 2013 Sep 23.

Sansom Institute, University of South Australia, Adelaide, South Australia, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jep.12081DOI Listing
February 2014

Nutlin-3a efficacy in sarcoma predicted by transcriptomic and epigenetic profiling.

Cancer Res 2014 Feb 13;74(3):921-31. Epub 2013 Dec 13.

Authors' Affiliations: Sarcoma Research Group, Discipline of Medicine, Centre for Personalised Cancer Medicine, Faculty of Health Sciences, School of Molecular and Biomedical Science, Departments of Orthopaedics and Trauma and Haematology, Cancer Clinical Trials Unit, Royal Adelaide Hospital; Department of Surgery, Royal Adelaide Hospital and University of Adelaide; ACRF Cancer Genomics Facility, Centre for Cancer Biology, Division of Tissue Pathology, SA Pathology; Centre for Neurological Diseases, Hanson Institute and SA Pathology; Department of Radiology, Queen Elizabeth Hospital; Department of Haematology and Oncology, Basil Hetzel Institute and Queen Elizabeth Hospital; University of Adelaide, Discipline of Surgery, Basil Hetzel Institute, Adelaide; Sarcoma Genomics and Genetics Laboratory, Peter MacCallum Cancer Centre, Melbourne, Australia; and Department of Medical Oncology, The Royal Melbourne Hospital, Parkville, Australia.

View Article

Download full-text PDF

Source
http://cancerres.aacrjournals.org/content/early/2014/01/23/0
Web Search
http://cancerres.aacrjournals.org/content/early/2013/12/13/0
Web Search
http://cancerres.aacrjournals.org/cgi/doi/10.1158/0008-5472.
Publisher Site
http://dx.doi.org/10.1158/0008-5472.CAN-13-2424DOI Listing
February 2014

Pre-activation of the p53 pathway through Nutlin-3a sensitises sarcomas to drozitumab therapy.

Oncol Rep 2013 Jul 13;30(1):471-7. Epub 2013 May 13.

Centre for Personalised Cancer Medicine, The University of Adelaide, Adelaide, South Australia, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3892/or.2013.2454DOI Listing
July 2013

A critical review of the role of Fc gamma receptor polymorphisms in the response to monoclonal antibodies in cancer.

J Hematol Oncol 2013 Jan 4;6. Epub 2013 Jan 4.

Pharmacy Department, Peter MacCallum Cancer Centre, St Andrew's Place, East Melbourne, Victoria, 3002, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/1756-8722-6-1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3549734PMC
January 2013

Current and emerging immunotherapeutic approaches to treat and prevent peanut allergy.

Expert Rev Vaccines 2012 Dec;11(12):1471-81

Experimental Therapeutics Laboratory, Hanson Institute, Frome Rd, Adelaide, SA 5000, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1586/erv.12.119DOI Listing
December 2012

Is the induction of tumor cell senescence the key to a good irradiated tumor vaccine?

Authors:
Michael P Brown

Mol Ther 2012 May;20(5):884-6

Discipline of Medicine, School of Medicine, University of Adelaide, Adelaide, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/mt.2012.72DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3345980PMC
May 2012

Innate immune recognition of poxviral vaccine vectors.

Expert Rev Vaccines 2011 Oct;10(10):1435-49

Experimental Therapeutics Laboratory, Hanson Institute, Royal Adelaide Hospital, Adelaide, SA, 5000, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1586/erv.11.121DOI Listing
October 2011

Breast cancer stem cells: treatment resistance and therapeutic opportunities.

Carcinogenesis 2011 May 10;32(5):650-8. Epub 2011 Feb 10.

Signal Transduction Lab, Queensland Institute of Medical Research, 300 Herston Road, Brisbane, Queensland 4006, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/carcin/bgr028DOI Listing
May 2011

Do human lymphocyte antigens play a role in the clinical antimelanoma activity of ipilimumab?

Authors:
Michael P Brown

Immunotherapy 2011 May;3(5):595-9

Cancer Clinical Trials Unit, Royal Adelaide Hospital Cancer Centre, Adelaide, SA, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/imt.11.23DOI Listing
May 2011

Nutlin-3a is a potential therapeutic for ewing sarcoma.

Clin Cancer Res 2011 Feb 23;17(3):494-504. Epub 2010 Nov 23.

Sarcoma Research Group, Discipline of Medicine, University of Adelaide and Hanson Institute Adelaide, South Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-10-1587DOI Listing
February 2011

Dasatinib alters the metastatic phenotype of B16-OVA melanoma in vivo.

Cancer Biol Ther 2010 Oct 1;10(7):715-27. Epub 2010 Oct 1.

Hanson Institute, Adelaide, The University of South Australia, South Australia, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4161/cbt.10.7.12926DOI Listing
October 2010

Unravelling the complexity of cancer-immune system interplay.

Expert Rev Anticancer Ther 2010 Jun;10(6):917-34

Experimental Therapeutic Laboratory, Hanson Institute & Sansom Institute, University of South Australia, SA, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1586/era.10.66DOI Listing
June 2010

Multifunctional core-shell magnetic cisplatin nanocarriers.

Chem Commun (Camb) 2009 Dec 3(47):7348-50. Epub 2009 Nov 3.

Ian Wark Research Institute, University of South Australia, Mawson Lakes, SA 5095, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1039/b911703bDOI Listing
December 2009

A simulation-approximation approach to sample size planning for high-dimensional classification studies.

Biostatistics 2009 Jul 21;10(3):424-35. Epub 2009 Feb 21.

Department of Environmental Science, Policy, & Management, University of California, 137 Hilgard Hall No. 3114, Berkeley, CA 94720-3114, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/biostatistics/kxp001DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2697341PMC
July 2009

Cross-presentation of male seminal fluid antigens elicits T cell activation to initiate the female immune response to pregnancy.

J Immunol 2009 Jun;182(12):8080-93

Research Centre for Reproductive Health, School of Paediatric and Reproductive Health, University of Adelaide, Adelaide, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4049/jimmunol.0804018DOI Listing
June 2009

A simplified suite of methods to evaluate chelator conjugation of antibodies: effects on hydrodynamic radius and biodistribution.

Nucl Med Biol 2009 May 26;36(4):395-402. Epub 2009 Mar 26.

Experimental Therapeutics Laboratory, Hanson Institute, Adelaide SA 5000, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.nucmedbio.2009.01.001DOI Listing
May 2009

Chemotherapy synergizes with radioimmunotherapy targeting La autoantigen in tumors.

PLoS One 2009 27;4(2):e4630. Epub 2009 Feb 27.

Experimental Therapeutics Laboratory, Hanson Institute, Adelaide, South Australia, Australia.

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0004630PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2645682PMC
April 2009

Transforming growth factor-beta-mediated signaling in T lymphocytes impacts on prostate-specific immunity and early prostate tumor progression.

Lab Invest 2009 Feb 15;89(2):142-51. Epub 2008 Dec 15.

Experimental Therapeutics Laboratory, Hanson Institute, Adelaide, SA, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/labinvest.2008.123DOI Listing
February 2009

Immunotargeting of Functional Nanoparticles for MRI detection of Apoptotic Tumor Cells.

Adv Mater 2009 Feb;21(5):541-5

Ian Wark Research Institute, University of South Australia SA 5095 (Australia).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/adma.200800998DOI Listing
February 2009

Midterm outcome after the distal revascularization and interval ligation (DRIL) procedure.

J Vasc Surg 2008 Oct 18;48(4):926-32; discussion 932-3. Epub 2008 Jul 18.

Division of Vascular Surgery and Endovascular Therapy, Department of Surgery, University of Florida College of Medicine, Gainesville, Fla, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jvs.2008.05.028DOI Listing
October 2008

Midterm outcomes of femoral arteries after percutaneous endovascular aortic repair using the Preclose technique.

J Vasc Surg 2008 May 6;47(5):919-23. Epub 2008 Mar 6.

University of Florida, Division of Vascular Surgery and Endovascular Therapy, Gainesville, FL 32610-0286, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jvs.2007.12.029DOI Listing
May 2008

Prolonged and severe myelosuppression in two patients after low-dose temozolomide treatment- case study and review of literature.

J Neurooncol 2007 Nov 26;85(2):229-30. Epub 2007 May 26.

Department of Medical Oncology, Royal Adelaide Hospital, Adelaide, SA, 5000, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11060-007-9403-6DOI Listing
November 2007

Early results after staged hybrid repair of thoracoabdominal aortic aneurysms.

J Am Coll Surg 2007 Sep 16;205(3):420-31. Epub 2007 Jul 16.

Division of Vascular Surgery and Endovascular Therapy, Department of Surgery, University of Florida College of Medicine, Gainesville, FL 32610-0286, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jamcollsurg.2007.04.016DOI Listing
September 2007

The La autoantigen is a malignancy-associated cell death target that is induced by DNA-damaging drugs.

Clin Cancer Res 2007 Sep;13(18 Pt 2):5509s-5518s

Experimental Therapeutics Laboratory, Hanson Institute, Department of Medical Oncology, Royal Adelaide Hospital, South Australia, Australia.

View Article

Download full-text PDF

Source
http://clincancerres.aacrjournals.org/cgi/doi/10.1158/1078-0
Publisher Site
http://dx.doi.org/10.1158/1078-0432.CCR-07-0922DOI Listing
September 2007

In vivo targeting of dead tumor cells in a murine tumor model using a monoclonal antibody specific for the La autoantigen.

Clin Cancer Res 2007 Sep;13(18 Pt 2):5519s-5527s

Experimental Therapeutics Laboratory, Hanson Institute, School of Pharmacy and Medical Sciences, University of South Australia, and Department of Medical Oncology, Royal Adelaide Hospital, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-07-0964DOI Listing
September 2007

Improving vaccines by incorporating immunological coadjuvants.

Expert Rev Vaccines 2007 Aug;6(4):559-78

Experimental Therapeutics Laboratory, Hanson Institute, and School of Pharmacy and Medical Sciences, Sansom Institute, University of South Australia, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1586/14760584.6.4.559DOI Listing
August 2007

Total percutaneous access for endovascular aortic aneurysm repair ("Preclose" technique).

J Vasc Surg 2007 Jun 29;45(6):1095-101. Epub 2007 Mar 29.

Division of Vascular Surgery and Endovascular Therapy, University of Florida College of Medicine, Gainesville, FL 32610-0286, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jvs.2007.01.050DOI Listing
June 2007

Functional characterization of spliceosomal introns and identification of U2, U4, and U5 snRNAs in the deep-branching eukaryote Entamoeba histolytica.

Eukaryot Cell 2007 Jun 27;6(6):940-8. Epub 2007 Apr 27.

Department of Medicine, Division of Infectious Diseases, Stanford University School of Medicine, 300 Pasteur Drive, Stanford, CA 94305, USA.

View Article

Download full-text PDF

Source
http://ec.asm.org/lookup/doi/10.1128/EC.00059-07
Publisher Site
http://dx.doi.org/10.1128/EC.00059-07DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1951529PMC
June 2007

The potential role of fowlpox virus in rational vaccine design.

Expert Rev Vaccines 2006 Aug;5(4):565-77

Experimental Therapeutics Laboratory, Hanson Institute, Level 4, Hanson Institute Building, Frome Road, Adelaide, South Australia, 5000, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1586/14760584.5.4.565DOI Listing
August 2006

Suppression of androgen receptor signaling in prostate cancer cells by an inhibitory receptor variant.

Mol Endocrinol 2006 May 19;20(5):1009-24. Epub 2006 Jan 19.

Dame Roma Mitchell Cancer Research Laboratories, Department of Medicine, The University of Adelaide, Hanson Institute, P.O. Box 14, Rundle Mall, Adelaide, South Australia 5000, Australia.

View Article

Download full-text PDF

Source
https://academic.oup.com/mend/article-lookup/doi/10.1210/me.
Publisher Site
http://dx.doi.org/10.1210/me.2004-0401DOI Listing
May 2006

Expression of Drosophila Ca2+ permeable transient receptor potential-like channel protein in a prostate cancer cell line decreases cell survival.

Cancer Gene Ther 2003 Aug;10(8):611-25

Department of Medical Biochemistry, School of Medicine, Faculty of Health Sciences, Flinders University, GPO Box 2100, Adelaide, South Australia 5001, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/sj.cgt.7700608DOI Listing
August 2003

CD40 ligand (CD154) improves the durability of respiratory syncytial virus DNA vaccination in BALB/c mice.

Vaccine 2003 Jun;21(21-22):2964-79

National Centers for Infectious Diseases, Division of Viral and Rickettsial Diseases, Respiratory and Enteric Virus Branch, 1600 Clifton Road NE, Mailstop G-09, Atlanta, GA 30333, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/s0264-410x(03)00119-1DOI Listing
June 2003

Complement-fixing CD45 monoclonal antibodies to facilitate stem cell transplantation in mouse and man.

Ann N Y Acad Sci 2003 May;996:80-8

Center for Cell and Gene Therapy and Department of Pediatrics, Baylor College of Medicine, Houston, Texas 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1749-6632.2003.tb03236.xDOI Listing
May 2003

Flt3 ligand expands dendritic cell numbers in normal and malignant murine prostate.

Immunol Cell Biol 2002 Aug;80(4):370-81

Arthritis Research Laboratory, Hanson Institute, Institute of Medical andVeterinary Science, Adelaide, SA, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1046/j.1440-1711.2002.01100.xDOI Listing
August 2002